Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by SanFrancisco99on Mar 18, 2015 4:45pm

230 Views

Post# 23535755

Supportive of a Phased Buyout Now???

A very interesting passage - which seems to indicate that partnering will come BEFORE the end of the development cycle for the compound (that quite possibily could mean NOW):

Business Strategy

Given the high costs, long development times and high attrition rates associated with drug development, many biotechnology companies seek the assistance of a pharmaceutical partner to advance their products through clinical trials. Resverlogix will seek to partner or license its pharmaceutical drug candidates at the stage that will provide shareholders with the optimal value for their investment. Should such partnering or licensing be successful, a pharmaceutical company will provide the funding and expertise to complete the latter stages of drug development and commercialization.

(Emphasis added - sounds like they are planning to license now. Could that mean a phased buyout???)

LINK: https://www.resverlogix.com/upload/media_element/208/01/leeuwenhoeck-research-initiation-report-rvx-march-16-2015.pdf